Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791

Last updated date
Study Location
Birmingham, Alabama, 35209, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Asthma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Moderate to severe persistent asthma for at least 1 year

- Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted

- Subjects must be on a high-dose inhaled corticosteroid (ICS)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous treatment with etanercept


- Current use of cigarettes


- Significant concurrent medical conditions at the time of screening

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AsthmaEvaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
NCT01172808
  1. Huntington Beach, California
  2. Mission Viejo, California
  3. San Diego, California
  4. Wheat Ridge, Colorado
  5. Coeur d'Alene, Idaho
  6. Normal, Illinois
  7. South Bend, Indiana
  8. Baltimore, Maryland
  9. North Dartmouth, Massachusetts
  10. North Dartmouth, Massachusetts
  11. Minneapolis, Minnesota
  12. Bellevue, Nebraska
  13. Boys Town, Nebraska
  14. Omaha, Nebraska
  15. Winston-Salem, North Carolina
  16. Oklahoma City, Oklahoma
  17. Charleston, South Carolina
  18. Easely, South Carolina
  19. Dallas, Texas
  20. Seattle, Washington
  21. Tacoma, Washington
  22. Juiz de Fora,
  23. Porto Alegre,
  24. Porto Alegre,
  25. Porto Alegre,
  26. Rio de Janeiro - RJ,
  27. Beijing,
  28. Beijing,
  29. Beijing,
  30. Beijing,
  31. Changsha,
  32. Chengdu,
  33. Chengdu,
  34. Chongqing,
  35. Guangzhou,
  36. Kunming,
  37. Qingdao,
  38. Shanghai,
  39. Shenyang,
  40. Shenyang,
  41. Xi'An,
  42. Guatelama City,
  43. Guatelmala city,
  44. Guatelmala City,
  45. Guatemala City,
  46. Guatemala city,
  47. Banglore,
  48. Chennai,
  49. Coimbatore,
  50. Coimbatore,
  51. Hyderabad,
  52. Jaipur,
  53. Nagpur,
  54. Pune,
  55. Pune,
  56. Adachi-ku, Tokyo,
  57. Ako, Hyogo,
  58. Chiyoda-ku, Tokyo,
  59. Chuo-ku, Tokyo,
  60. Chuo-ku, Tokyo,
  61. Fujioka, Gunma,
  62. Himeji, Hyogo,
  63. Hitachi, Ibaraki,
  64. Iwamizawa, Hokkaido,
  65. Kanazawa, Ishikawa,
  66. Kitakami, Iwate,
  67. Kitakami, Iwate,
  68. Koga, Ibaraki,
  69. Koganei, Tokyo,
  70. Komaki, Aichi,
  71. Kunitachi, Tokyo,
  72. Mito, Ibaraki,
  73. Osaka, Osaka,
  74. Ota-ku, Tokyo,
  75. Sapporo, Hokkaido,
  76. Sendai, Miyagi,
  77. Sendai, Miyagi,
  78. Setagaya-ku, Tokyo,
  79. Takasaki, Gunma,
  80. Tomakomai, Hokkaido,
  81. Toshima-ku, Tokyo,
  82. Toshima-ku, Tokyo,
  83. Yao, Osaka,
  84. Yokohama, Kanagawa,
  85. Yokohama, Kanagawa,
  86. Daugavpils,
  87. Preili,
  88. Riga,
  89. Riga,
  90. Riga,
  91. Riga,
  92. Riga,
  93. Riga,
  94. Ventspils,
  95. Monterrey,
  96. Zapopan,
  97. Zona Río,
  98. Callao,
  99. Lima,
  100. Lima,
  101. Krakow,
  102. Lodz,
  103. Lodz,
  104. Ostrow Wielkopolska,
  105. Poznan,
  106. Tczew,
  107. Gatchina (Leningradskaya oblast),
  108. Moscow,
  109. Moscow,
  110. Moscow,
  111. Moscow,
  112. St. Petersburg,
  113. St. Petersburg,
  114. St. Petersburg,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEvaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
NCT01172821
  1. Los Angeles, California
  2. Stockton, California
  3. Centennial, Colorado
  4. Denver, Colorado
  5. Panama City, Florida
  6. Winter Park, Florida
  7. Novi, Michigan
  8. Plymouth, Minnesota
  9. St. Louis, Missouri
  10. Bozeman, Montana
  11. Skillman, New Jersey
  12. Raleigh, North Carolina
  13. Cincinnati, Ohio
  14. Portland, Oregon
  15. Greenville, South Carolina
  16. Union, South Carolina
  17. El Paso, Texas
  18. San Antonio, Texas
  19. Florianopolis,
  20. Porto Alegre,
  21. Sao Paulo,
  22. Sao Paulo,
  23. Chengdu,
  24. Chongqing,
  25. Guangzhou,
  26. Guangzhou,
  27. Haikou,
  28. Kunming,
  29. Nanchang,
  30. Nanjing,
  31. Shanghai,
  32. Shanghai,
  33. Shanghai,
  34. Shanghai,
  35. Xi'An,
  36. Xi'An,
  37. Xuzhou,
  38. Yangzhou,
  39. Yinchuan,
  40. Bogota,
  41. Bogota,
  42. Bogota,
  43. Medelin,
  44. Bamberg,
  45. Berlin,
  46. Berlin,
  47. Berlin,
  48. Berlin,
  49. Berlin,
  50. Frankfurt,
  51. Hamburg,
  52. Koblenz,
  53. Lübeck,
  54. Rüdersdorf,
  55. Wiesbaden,
  56. Witten,
  57. Ahmedabad,
  58. Coimbatore,
  59. Hyderabad,
  60. Jaipur,
  61. Jaipur,
  62. Mumbai,
  63. Mysore,
  64. Nagpur,
  65. Aira, Kagoshima,
  66. Chuo-ku, Tokyo,
  67. Fukuoka, Fukuoka,
  68. Fukuoka, Fukuoka,
  69. Fukuyama, Hiroshima,
  70. Habikino, Osaka,
  71. Hiroshima, Hiroshima,
  72. Itabashi-ku, Tokyo,
  73. Iwata, Shizuoka,
  74. Kanazawa, Ishikawa,
  75. Kishiwada, Osaka,
  76. Kitakyushu, Fukuoka,
  77. Kobe, Hyogo,
  78. Koto-ku, Tokyo,
  79. Kyoto, Kyoto,
  80. Matsusaka, Mie,
  81. Meguro-ku, Tokyo,
  82. Minato-ku, Tokyo,
  83. Minato-ku, Tokyo,
  84. Morioka, Iwate,
  85. Naka-gun, Ibaraki,
  86. Nakano-ku,Tokyo,
  87. Oita,Oita,
  88. Osaka-Sayama, Osaka,
  89. Sapporo, Hokkaido,
  90. Sendai, Miyagi,
  91. Seto, Aichi,
  92. Shinagawa-ku, Tokyo,
  93. Shizuoka, Shizuoka,
  94. Toyota, Aichi,
  95. Urasoe, Okinawa,
  96. Urasoe, Okinawa,
  97. Urasoe, Okinawa,
  98. Yokohama, Kanagawa,
  99. Yotsukaido, Chiba,
  100. Mexico City,
  101. Mexico City,
  102. Monterrey,
  103. Lima,
  104. Lima,
  105. Lima,
  106. Lima,
  107. Lima,
  108. Bialystok,
  109. Bydgoszcz,
  110. Gorzow Wielkopolski,
  111. Krakow,
  112. Poznan,
  113. Sopot,
  114. Wloszczowa,
  115. Wroclaw,
  116. Brasov,
  117. Brasov,
  118. Bucharest,
  119. Bucharest,
  120. Bucharest,
  121. Bucharest,
  122. Bucharest,
  123. Bucuresti,
  124. Constanta,
  125. Iasi,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AsthmaEfficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
NCT01122680
  1. Denver, Colorado
  2. Columbia, Missouri
  3. Warrensburg, Missouri
  4. Boys Town, Nebraska
  5. Canton, Ohio
  6. Koblenz,
  7. Rosenheim,
  8. Wesel,
  9. Balvi,
  10. Daugavpils,
  11. Rezekne,
  12. Riga,
  13. Riga,
  14. Vilnius,
  15. Vilnius,
  16. Vilnius,
  17. Kamnik,
  18. Ljubljana,
  19. Maribor,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
AsthmaRandomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284
  1. Hallein,
  2. Linz,
  3. Neumarkt am Wallersee,
  4. Schlüsslberg,
  5. Thalheim bei Wels,
  6. Berlin,
  7. Berlin,
  8. Frankfurt,
  9. Hamburg,
  10. Hannover,
  11. Mainz,
  12. Schwerin,
  13. Wiesbaden,
  14. Wiesloch,
  15. Ivano-Frankivsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kiev,
  19. Kiev,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Etanercept in Moderate to Severe Asthma
Official Title  ICMJE A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma
Brief Summary The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE Drug: Etanercept
Study Arms  ICMJE Not Provided
Publications * Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011 Jun;37(6):1352-9. doi: 10.1183/09031936.00063510. Epub 2010 Nov 25.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 30, 2005)
120
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2006
Actual Primary Completion Date July 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Moderate to severe persistent asthma for at least 1 year
  • Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
  • Subjects must be on a high-dose inhaled corticosteroid (ICS)

Exclusion Criteria:

  • Previous treatment with etanercept
  • Current use of cigarettes
  • Significant concurrent medical conditions at the time of screening
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00141791
Other Study ID Numbers  ICMJE 0881A8-205
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP